Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial

Lavezzi, Silvia; de Jong, Jan; Neyens, Martine; Cramer, Paula; DEMİRKAN, FATİH; Fraser, Graeme; Bartlett, Nancy; Dilhuydy, Marie-Sarah; Loscertales, Javier; Avigdor, Abraham; Rule, Simon; Samoilova, Olga; Goy, Andre; Ganguly, Siddhartha; Salman, Mariya; Howes, Angela; Mahler, Michelle; De Nicolao, Giuseppe; Poggesi, Italo

doi:10.1007/s11095-019-2605-8

Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial

Copy For Citation

Lavezzi S. M., de Jong J., Neyens M., Cramer P., DEMİRKAN F., Fraser G., ...More

PHARMACEUTICAL RESEARCH, vol.36, no.7, 2019 (SCI-Expanded)

Publication Type: Article / Article
Volume: 36 Issue: 7
Publication Date: 2019
Doi Number: 10.1007/s11095-019-2605-8
Journal Name: PHARMACEUTICAL RESEARCH
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Keywords: bendamustine, ibrutinib, modeling, pharmacokinetics, rituximab, CHRONIC LYMPHOCYTIC-LEUKEMIA, MULTICENTER PHASE-II, TARGET, BENDAMUSTINE, ASSOCIATION, ELIMINATION, CLEARANCE, BTK
Dokuz Eylül University Affiliated: Yes

Abstract

Introduction In the HELIOS trial, bendamustine/rituximab (BR) plus ibrutinib (BR-I) improved disease outcomes versus BR plus placebo in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma. Here, we describe the pharmacokinetic (PK) observations, along with modeling to further explore the interaction between ibrutinib and rituximab.